{"schema_version":"secwatch.filing_event.v1","accession":"0000926326-26-000019","form_type":"8-K","ticker":"OMCL","cik":"0000926326","company_name":"OMNICELL, INC.","filed_at":"2026-07-30T10:34:15+00:00","discovered_at":"2026-07-30T10:35:00.345271+00:00","generated_at":"2026-07-30T10:35:04.885478+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Omnicell Q2 revenue $312M (+7% YoY); raises FY non-GAAP EPS and EBITDA guidance","bullets":["GAAP net income $24M ($0.52 diluted EPS) vs $6M ($0.12) YoY; non-GAAP EPS $0.94 vs $0.45.","Non-GAAP EBITDA $67M vs $38M YoY; received $15M in IEEPA tariff refunds.","FY2026 guidance raised: non-GAAP EBITDA $175M-$185M, non-GAAP EPS $2.15-$2.30.","Nnamdi Njoku promoted to President and COO effective July 1, 2026.","Added Rick Couldry as SVP Chief Pharmacy & Clinical Officer and Dan Mandoli as SVP/GM Specialty Pharmacy."],"urls":{"canonical":"https://secwatch.observer/filing/0000926326-26-000019","json":"https://secwatch.observer/filing/0000926326-26-000019.json","markdown":"https://secwatch.observer/filing/0000926326-26-000019.md","text":"https://secwatch.observer/filing/0000926326-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926326/000092632626000019/0000926326-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926326/000092632626000019/omcl-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T10:35:04.885478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}